- Integer’s adjusted earnings per share (EPS) for Q1 is $1.31, higher than both the previous year’s $1.14 and analysts’ estimate of $1.24.
- Sales reached $437.4 million, marking a 5.4% increase from the previous year and surpassing the estimate of $428.9 million.
- Adjusted EBITDA was $91.5 million, up 13% year-over-year, beating the anticipated $89.1 million.
- Adjusted operating income increased by 13% from last year, totaling $70.9 million, above the projected $68 million.
- The company maintains its forecast for capital expenditure between $110 million and $120 million for the year.
- Analyst consensus includes 9 buy ratings, 2 hold ratings, and no sell ratings.
A look at Integer Holdings Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Integer Holdings Corporation, a medical device manufacturing company, shows a promising long-term outlook based on its Smartkarma Smart Scores. With a solid score of 4 in Growth and Momentum, the company is positioned well to capitalize on future opportunities in the market. Integer Holdings’ focus on developing innovative medical devices and power solutions highlights its potential for sustained growth in the industry.
Moreover, the company’s emphasis on resilience, reflected in its score of 3, indicates its ability to navigate challenges and adapt to changing market conditions. While the Dividend score of 1 suggests limited dividend payouts, Integer Holdings’ overall profile showcases a strong foundation for long-term success in serving patients globally with cutting-edge medical solutions.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
